Johnson & Johnson EPS - Earnings per Share 2006-2018 | JNJ

Johnson & Johnson annual and quarterly earnings per share history from 2006 to 2018. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Johnson & Johnson EPS for the quarter ending September 30, 2018 was $1.44, a 5.11% increase year-over-year.
  • Johnson & Johnson EPS for the twelve months ending September 30, 2018 was $0.58, a 89.93% decline year-over-year.
  • Johnson & Johnson 2017 annual EPS was $0.47, a 92.07% decline from 2016.
  • Johnson & Johnson 2016 annual EPS was $5.93, a 8.21% increase from 2015.
  • Johnson & Johnson 2015 annual EPS was $5.48, a 3.86% decline from 2014.
Johnson & Johnson Annual EPS
2017 $0.47
2016 $5.93
2015 $5.48
2014 $5.70
2013 $4.81
2012 $3.86
2011 $3.49
2010 $4.78
2009 $4.40
2008 $4.57
2007 $3.63
2006 $3.73
2005 $3.35
Johnson & Johnson Quarterly EPS
Q3 2018 $1.44
Q2 2018 $1.45
Q1 2018 $1.60
Q4 2017 $-3.91
Q3 2017 $1.37
Q2 2017 $1.40
Q1 2017 $1.61
Q4 2016 $1.38
Q3 2016 $1.53
Q2 2016 $1.43
Q1 2016 $1.59
Q4 2015 $1.14
Q3 2015 $1.20
Q2 2015 $1.61
Q1 2015 $1.53
Q4 2014 $0.89
Q3 2014 $1.66
Q2 2014 $1.51
Q1 2014 $1.64
Q4 2013 $1.22
Q3 2013 $1.04
Q2 2013 $1.33
Q1 2013 $1.22
Q4 2012 $0.90
Q3 2012 $1.05
Q2 2012 $0.50
Q1 2012 $1.41
Q4 2011 $0.09
Q3 2011 $1.15
Q2 2011 $1.00
Q1 2011 $1.25
Q4 2010 $0.70
Q3 2010 $1.23
Q2 2010 $1.23
Q1 2010 $1.62
Q4 2009 $0.79
Q3 2009 $1.20
Q2 2009 $1.15
Q1 2009 $1.26
Q4 2008 $0.97
Q3 2008 $1.17
Q2 2008 $1.17
Q1 2008 $1.26
Q4 2007 $0.82
Q3 2007 $0.88
Q2 2007 $1.05
Q1 2007 $0.88
Q4 2006 $0.74
Q3 2006 $0.94
Q2 2006 $0.95
Q1 2006 $1.10
Q4 2005 $0.70
Q3 2005 $0.85
Q2 2005 $0.86
Q1 2005 $0.94
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $388.162B $76.450B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $259.069B 14.60
Novartis AG (NVS) Switzerland $204.655B 17.49
Merck (MRK) United States $201.163B 17.43
AbbVie (ABBV) United States $132.702B 11.78
Eli Lilly (LLY) United States $119.057B 20.93
Sanofi (SNY) France $112.613B 13.94
Novo Nordisk (NVO) Denmark $107.980B 17.54
AstraZeneca (AZN) United Kingdom $105.090B 13.05
GlaxoSmithKline (GSK) United Kingdom $102.669B 13.80
Bristol-Myers Squibb (BMY) United States $85.837B 14.14